RecruitingPHASE1INTERVENTIONAL
Nebulized MSC-Exos for Anti-MDA5+ RP-ILD: Safety and Efficacy Trial
- Sponsor:
- Li Shiyue
- Conditions:
- Anti-MDA5 Positive Dermatomyositis-Associated RP-ILD, Rapidly Progressive Interstitial Lung Disease
- Enrollment:
- 10
- Started:
- Apr 2025
NCT06919380